The present disclosure relates to the use MNK-specific inhibitors to inhibitimmunosuppression components, such asimmune checkpoint proteins PD-1, PD-L1, LAG3, and/or immunosuppressivecytokines, such as IL-10, in order to inhibit or releaseimmune suppression in certain diseases, such as cancer and infectious disease.